More than 800 people have been treated with Elevidys, the only approved treatment for Duchenne muscular dystrophy, the ...

Sarepta Therapeutics said on Tuesday that a 16-year-old boy died from acute liver failure months after receiving the company's U.S-approved gene therapy for a rare muscular dystrophy.

Therapeutics shared the following update related to ELEVIDYS, the only approved gene therapy in patients with Duchenne muscular ...

The shares are down 9%, or $5.53, to $56.94 in premarket trading. Don't Miss Our End of Quarter Offers: Discover the latest stocks recommended ...

Sarepta Therapeutics said on Friday it had temporarily halted three trials testing its gene therapy Elevidys, following the death of a patient last month upon receiving the treatment.